Skip to main content
FDA pushes for age diversity in cancer drug trials
3/10/2020

The FDA is encouraging sponsors of clinical trials for cancer drugs to enroll more patients older than 65, beginning with early-stage studies, when it is safe and ethical to do so. In draft guidance, the FDA says older patients should be recruited in early-stage studies "to obtain information on safety, exposure, and response to better inform the study design and dose selection of later phase studies."

Full Story: